The U.S. Securities and Exchange Commission (SEC) is signaling support for streamlined “minimum effective dose” disclosure rules and tightly scoped equity‑tokenization pilots via an innovation exemption, according to new remarks from Chair Paul S. Atkins. The U.S. Securities and Exchange…News, Cryptocurrency, DeFi, ExchangeRead More

You might also be interested in reading EQS-PVR: CTS Eventim AG & Co. KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution.